Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Sold by Janney Montgomery Scott LLC

Janney Montgomery Scott LLC decreased its stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) by 12.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 9,840 shares of the company’s stock after selling 1,454 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Ionis Pharmaceuticals were worth $344,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Geode Capital Management LLC boosted its holdings in Ionis Pharmaceuticals by 7.4% in the 3rd quarter. Geode Capital Management LLC now owns 2,668,358 shares of the company’s stock worth $106,922,000 after buying an additional 183,814 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Ionis Pharmaceuticals by 8.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,443,020 shares of the company’s stock worth $57,807,000 after acquiring an additional 114,914 shares during the last quarter. ARK Investment Management LLC increased its position in shares of Ionis Pharmaceuticals by 1.7% during the third quarter. ARK Investment Management LLC now owns 1,384,269 shares of the company’s stock worth $55,454,000 after purchasing an additional 23,244 shares in the last quarter. Two Sigma Advisers LP raised its stake in Ionis Pharmaceuticals by 3.5% in the 3rd quarter. Two Sigma Advisers LP now owns 1,332,411 shares of the company’s stock valued at $53,376,000 after purchasing an additional 45,300 shares during the last quarter. Finally, Groupama Asset Managment lifted its holdings in Ionis Pharmaceuticals by 4.1% in the 3rd quarter. Groupama Asset Managment now owns 916,060 shares of the company’s stock valued at $367,000 after purchasing an additional 36,084 shares in the last quarter. Hedge funds and other institutional investors own 93.86% of the company’s stock.

Insider Activity

In other news, EVP Eric Swayze sold 1,367 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $32.31, for a total value of $44,167.77. Following the completion of the transaction, the executive vice president now owns 48,017 shares of the company’s stock, valued at approximately $1,551,429.27. This trade represents a 2.77 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Brett P. Monia sold 38,843 shares of the company’s stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $31.65, for a total transaction of $1,229,380.95. Following the sale, the chief executive officer now directly owns 180,683 shares in the company, valued at approximately $5,718,616.95. The trade was a 17.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 110,609 shares of company stock valued at $3,564,867. 2.71% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

IONS has been the subject of a number of research reports. Needham & Company LLC reaffirmed a “buy” rating and set a $60.00 target price on shares of Ionis Pharmaceuticals in a report on Friday, December 20th. StockNews.com downgraded shares of Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, November 12th. Piper Sandler lowered their target price on Ionis Pharmaceuticals from $65.00 to $62.00 and set an “overweight” rating on the stock in a report on Thursday, November 14th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $70.00 price target on shares of Ionis Pharmaceuticals in a report on Wednesday, January 15th. Finally, William Blair reissued an “outperform” rating on shares of Ionis Pharmaceuticals in a research note on Friday, December 20th. Two research analysts have rated the stock with a sell rating, five have given a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $60.65.

Ionis Pharmaceuticals Stock Up 0.3 %

Ionis Pharmaceuticals stock opened at $31.48 on Tuesday. The company has a market capitalization of $4.97 billion, a PE ratio of -12.90 and a beta of 0.34. The company has a debt-to-equity ratio of 1.86, a quick ratio of 8.82 and a current ratio of 8.91. Ionis Pharmaceuticals, Inc. has a fifty-two week low of $31.03 and a fifty-two week high of $52.34. The firm has a 50 day moving average price of $34.70 and a 200 day moving average price of $39.36.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.